Clinical Trials/IRCT20180113038331N1

IRCT20180113038331N1

Recruiting

Phase 2

Treatment of castration-resistant metastatic prostate cancer, refractory to routine treatment with Lu177-PSMA

Mashhad University of Medical Sciences0 sites20 target enrollmentTBD

ConditionsCastration resistant metastatic prostate cancer.Malignant neoplasm of prostate

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Castration resistant metastatic prostate cancer.
Sponsor: Mashhad University of Medical Sciences
Enrollment: 20
Status: Recruiting
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

8 years ago

Study Type

Interventional

Sex

Male

Investigators

Sponsor

Mashhad University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

•Patients with Hx of metastatic prostate cancer resistant to usual treatment
•Positive Ga68\-PSMA PET/CT scan

Exclusion Criteria

•survival less than 4 months
•GFR less than 40cc/min
•?Serum creatinin \>1\.5
•Urinary tract obstruction
•Bone marrow suppression (WBC \<2500 Plat\<80000 Hct\<8

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Response evaluation with 68Ga-PSMA PET of metastatic prostate cancer castration resistant patients in treatment with 223RaCl2Patients mCRPC eligible to treatment with 223RaCl2MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10036223Term: Positron emission tomographySystem Organ Class: 100000004848MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2017-001395-38-ITAZIENDA USL DELLA VALLE D'AOSTA50

Not yet recruiting

Targeted a-Therapy in Prostate CancerProstate cancer.Malignant neoplasm of prostate

IRCT20210612051548N1Boushehr University of Medical Sciences10

Metastatic hormone-sensitive and castration resistant prostate cancer registry: CAPRI 3.0

NL-OMON24783Radboud University Medical Center10,000

Prospective observational study of castration-resistant prostate cancer with homologous recombination repair-related gene mutations.prostate cancerD011471

JPRN-jRCT1050230026Goto Takayuki400

Active, not recruiting

STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

EUCTR2004-000193-31-GBniversity College London12,000